Submit a Manuscript to the Journal
Geriatric Pharmacology
For an Article Collection on
Model-Informed Drug Development for Geriatric Populations
Manuscript deadline
Article Collection Guest Advisor(s)
Dr. Victor Crentsil,
Johns Hopkins University School of Medicine
Vcrents2@jh.edu
Benefits of Publishing in an Article Collection
An Article Collection is an opportunity for your research to reach the right audience. Bringing together the work of the global research community, Collections provide readers with a central place to find the latest research on emerging and important topics. They have been found to increase the discoverability and visibility of each article, as well as article-level citations.
Model-Informed Drug Development for Geriatric Populations
Model-Informed Drug Development (MIDD) is a methodologic paradigm that leverages mathematical or computational modelling and simulation. It combines non-clinical and clinical data and other existing knowledge to generate evidence that facilitates decision-making during drug development. It is transforming approaches to evidence synthesis and integration, as well as provision of actionable insights for contemporary development of therapeutic products.
Although the modifying effects of aging on drug pharmacokinetics (PK) and pharmacodynamics (PD) are widely known, older adults are under-represented in drug development programs, which has resulted in evidence gaps in geriatric therapeutics. Geriatric under-representation in drug development programs is multifactorial; however, MIDD, through its utility for optimizing study design, dose selection, benefit-risk evaluation, increasing efficiency, decreasing development costs and time, and minimizing risk, is likely to accelerate the closure of evidence gaps in geriatric therapeutics than traditional methods. MIDD is enjoying growing endorsement of regulatory authorities and its risk minimizing attributes makes it advantageous for high-risk populations. Consequently, highlighting MIDD’s achievements in older populations is likely to facilitate its widespread consideration for advancing geriatric pharmacology. Geriatric populations are increasing worldwide; therefore, the earlier MIDD is promoted and implemented in older populations, the sooner the benefits will be realized globally.
Subtopics of interest may include but not limited to:
- Applications of MIDD in Geriatric Populations
- Advanced Aging and its Impact on Model Development, Evaluation, and Implementation
- Potential Challenges in Using MIDD to Document Evidence in Geriatric Populations
- Leveraging Artificial Intelligence/Machine Learning to Facilitate or Enhance Model Development and Decision-Making in Geriatric Therapeutics
- Utilizing MIDD to Accelerate Therapeutic Development for Alzheimer’s and Other Dementias
- MIDD for Geriatric Frailty and other Syndromes Prevalent in Older Populations
- MIDD for Enriching Geriatric Subsection of Labelling of Therapeutics
- Model-Based Meta-Analysis for Benefit-Risk Assessments of Therapeutics in Geriatric Populations
- Disease Progression Models for Development of Drugs Predominantly Used in Geriatric Populations
- Engaging with Regulatory Authorities to Facilitate Acceptance of MIDD for Therapeutic Products Predominantly Used by Geriatric Populations
Keywords:
- Aging
- Geriatrics
- Drug Development
- Modelling and Simulation
- Quantitative Pharmacology
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review if they can pass the desk assessments as part of our standard editorial process; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).
The deadline for submitting manuscripts is 31 October 2026.
Please contact Catherine Teng at catherine.teng@taylorandfrancis.com with any queries and discount codes regarding this Article Collection.
Benefits of publishing open access within Taylor & Francis
Sustained readership
Publishing in an Article Collection ensures your research reaches a wide and engaged audience, driving long-term readership and citation impact.
Enhanced visibility
Gain recognition by showcasing your work in a trusted and reputable platform, amplifying your research’s visibility and influence.
Trends and methodologies
Connect with emerging topics and methodologies, positioning your research at the forefront of innovation and shaping the future of your field.
Support
Receive expert guidance at every stage of the publishing process from our experienced journal team, ensuring a seamless experience.
Network
Expand your professional network by collaborating with leading researchers from around the world, fostering interdisciplinary connections.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this Collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.